A groundbreaking study, spearheaded by Eunjoon Kim, Director of the IBS Center for Synaptic Brain Dysfunctions, has unveiled a potentially transformative therapeutic avenue for neurodevelopmental conditions, including autism spectrum disorder (ASD), by precisely modulating a key brain receptor system. The research centers on the glycine transporter known as Slc6a20a (or SLC6A20 in humans), a molecule whose activity plays a critical role in regulating neuronal communication. By selectively inhibiting this transporter, scientists have demonstrated a capacity to re-establish the optimal functioning of NMDA receptors (NMDARs), which are fundamental to a myriad of cognitive processes such as learning, memory formation, and synaptic plasticity.
The intricate dance of neurotransmission relies heavily on the balanced activity of NMDARs, crucial mediators of signals between nerve cells. A deficit in NMDAR functionality has been implicated in a spectrum of neurological and psychiatric disorders, ranging from autism spectrum disorder and schizophrenia to intellectual disabilities and even autoimmune conditions like NMDAR encephalitis. For decades, the scientific community has grappled with the challenge of enhancing NMDAR activity. While early therapeutic strategies aimed at increasing the availability of glycine, an essential co-agonist for NMDAR activation, by targeting another glycine transporter, GlyT1, these efforts encountered significant limitations. GlyT1’s widespread presence, particularly in brainstem regions vital for autonomic functions like respiration and motor control, meant that interventions designed to block it often yielded a mixed bag of results, frequently accompanied by undesirable systemic side effects.
This new research distinguishes itself by pursuing a more refined intervention. Unlike GlyT1, the Slc6a20a transporter exhibits a more constrained distribution, being primarily concentrated in brain areas intrinsically involved in higher cognitive functions, such as the cerebral cortex and the hippocampus. This localized presence offers a strategic advantage, presenting the potential to fine-tune NMDAR activity within these critical regions without significantly disrupting other essential neural pathways or vital physiological processes. The implication is a more targeted and potentially safer therapeutic modality.
To investigate this novel strategy, the research team employed antisense oligonucleotides (ASOs), a class of synthetic RNA molecules designed to bind to and degrade specific messenger RNA (mRNA) transcripts, thereby reducing the production of the targeted protein. In this study, ASOs were utilized to diminish the expression of Slc6a20a. These experiments were conducted using established mouse models engineered to carry mutations in the SHANK2 and SHANK3 genes. These genes are recognized as significant genetic contributors to autism spectrum disorder and are also associated with other complex neurodevelopmental conditions, including Phelan-McDermid syndrome.
The results emanating from these preclinical trials were striking. The administration of Slc6a20a ASOs effectively restored NMDAR function across several of the autism-related mouse models. Concurrently, the treated mice exhibited notable improvements in behaviors typically associated with ASD, including enhancements in social interaction and communication, alongside a reduction in repetitive behaviors. A particularly compelling aspect of these findings is that the observed benefits were evident even in adult mice. This observation carries profound implications, suggesting that the dysregulation of NMDAR function, even after critical periods of brain development have passed, may remain amenable to therapeutic intervention.
Delving deeper into the molecular mechanisms underlying these behavioral improvements, the researchers utilized sophisticated, large-scale phospho-proteomic analyses. These advanced techniques revealed that the ASO treatment did not significantly alter the overall abundance of proteins within the targeted brain regions. Instead, the therapy appeared to correct aberrant phosphorylation patterns in proteins critical for regulating synaptic signaling and NMDAR activity. Phosphorylation, a post-translational modification, is a key mechanism for fine-tuning protein function. The observed correction of these patterns suggests that the therapeutic approach works by restoring the proper functional state of these regulatory proteins, rather than simply by increasing or decreasing their overall quantities.
To assess the translational potential of this therapeutic strategy for human application, the researchers extended their investigations to human brain organoids. These three-dimensional cellular structures, derived from human stem cells and engineered to mimic aspects of the developing human brain, provided a valuable in vitro model. Using CRISPR gene editing technology, the scientists generated cortical organoids carrying mutations in the SHANK2 or SHANK3 genes. Consistent with the observations in the mouse models, these human organoids displayed diminished NMDAR activity. Subsequently, an ASO specifically designed to target the human SLC6A20 gene was introduced. This intervention successfully restored NMDAR function in the genetically modified organoids, bringing it to levels comparable to those found in healthy control organoids.
Director Eunjoon Kim commented on the significance of these findings, stating, "Unlike gene re-expression strategies, SLC6A20 inhibition works by modulating endogenous signaling pathways and may offer a more practical therapeutic route." He further emphasized the broad applicability of the approach, noting, "The fact that the effect was reproduced not only in mice but also in human cortical organoids suggests that this approach may represent a promising therapeutic strategy for neurodevelopmental disorders characterized by NMDA receptor hypofunction." This comparison to gene re-expression highlights the potential advantages of a modulatory approach, which aims to correct existing signaling imbalances rather than attempting to introduce or replace genetic material.
Furthermore, the durability of the treatment’s effects was a crucial finding. The research indicated that a single administration of the ASO maintained its efficacy for a minimum of eight weeks in the treated mice. Critically, no discernible adverse effects were detected in these animals during this observation period, underscoring the potential safety profile of this targeted intervention.
While the primary focus of this study was autism spectrum disorder, the underlying mechanism holds promise for a broader spectrum of neurological conditions. The well-established link between reduced NMDAR activity and disorders such as schizophrenia and certain forms of intellectual disability suggests that this therapeutic strategy could potentially benefit individuals affected by these conditions as well. The research thus identifies SLC6A20 as a compelling therapeutic target for the restoration of NMDAR function and lays a foundation for the development of novel treatments for a wider array of neurodevelopmental and neuropsychiatric disorders characterized by impaired NMDAR signaling. The meticulous investigation into this glycine transporter’s role and the development of a targeted inhibitory approach represent a significant stride forward in the quest for effective therapies for complex brain disorders.
About the Author
